Most recent update: Thursday, November 22, 2018 - 07:44

Bariatric News - Cookies & privacy policy

You are here

EndoBarrier data

ABCD EndoBarrier Registry shows metabolic improvements

Data from 12 patients six months after the removal of EndoBarrier demonstrates an average weight loss of more than 14kg from the baseline and average reduction in BMI of 5.6 points

Data from a UK National Health Service (NHS) EndoBarrier Registry presented at the American Diabetes Association’s 77th Scientific Sessions demonstrated that metabolic improvements made by patients while implanted with EndoBarrier were sustained six months after EndoBarrier was explanted.

The poster presentation, ‘Maintenance of Efficacy After Endobarrier in UK 1st National Health Service (NHS) Endobarrier Service,’ detailed data from 12 patients in the inaugural NHS EndoBarrier service at City Hospital in Birmingham, UK. These patients completed a 12-month implantation of EndoBarrier and were evaluated six months following explantation: 75 percent (nine out of the 12) sustained considerable metabolic improvements, including weight loss, BMI reduction and lower glucose levels (Table 1).

“This data from the ABCD Worldwide EndoBarrier Registry is from a range of patients from our practice who remained obese and with poor diabetes control despite all of the standard treatments,” said Dr Robert Ryder, consulting diabetologist at City Hospital.  “The intent of this study was to evaluate the effect of EndoBarrier in a real-world practice environment.”

Data from 12 patients six months after the removal of EndoBarrier demonstrates an average weight loss of more than 14kg from the baseline and average reduction in BMI of 5.6 points. Additionally, HbA1c levels in patients decreased by an average 26.7mmol/mol or an average of 2.0 percent from baseline levels.

Table 1: ABCD outcomes in 12 patients at baseline, six-month, 12-month and six-month explant

“Understanding the longer-term impact of Endobarrier is essential as we consider different metabolic interventions to address obesity and type 2 diabetes,” added Ryder. “In addition to sustained weight loss, BMI reduction and glucose improvement, these patients self-reported considerable improvements in wellbeing, energy, fitness and exercise ability.  Most exciting is that three of nine patients discontinued insulin at month twelve, and the fourth patient eliminated insulin during the six months post explant.”

Nine of the 12 patients in the study were treated with insulin prior to the implantation of EndoBarrier. At six months post-explantation, four patients representing 44 percent of those insulin-treated patients were able to discontinue insulin entirely.

“The team at City Hospital in Birmingham created the first NHS service and with that service have demonstrated that EndoBarrier is highly effective in treating patients with refractory type 2 diabetes and obesity,” said Scott Schorer, president and chief executive officer of GI Dynamics. “Most notable is the durability data showing retention of much of the HbA1c reductions despite significant reductions in median insulin usage at six months post explant from 104 iu/day to 10 iu/day. In addition to strong durability data six months following the removal of EndoBarrier, the patients themselves gave this innovative procedure high marks. Eighty-one percent of the patients would be highly likely to recommend EndoBarrier to friends and family members.”

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.